US Patent Issued to Fred Hutchinson Cancer Center on Aug. 25 for "Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor" (Washington Inventors)

ALEXANDRIA, Va., Aug. 25 -- United States Patent no. 12,714,722, issued on Aug. 25, was assigned to Fred Hutchinson Cancer Center (Seattle).

"Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor" was invented by David Hockenbery (Seattle) and Patrick Paddison (Seattle).

According to the abstract* released by the U.S. Patent & Trademark Office: "Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor in combination with a nicotinamide adenine dinucleotide (NAD) salvage pathway precursor are described. Cancers treated with the combination therapies can be nicotinamide riboside kinas...